Berberine restrains non-small cell lung cancer cell growth, invasion and glycolysis via inactivating the SPC25/NUF2 pathway
- PMID: 39755832
- DOI: 10.1007/s00210-024-03729-w
Berberine restrains non-small cell lung cancer cell growth, invasion and glycolysis via inactivating the SPC25/NUF2 pathway
Abstract
Berberine (BBR) has been proved to inhibit the malignant progression of non-small cell lung cancer (NSCLC), but the underlying molecular mechanism still needs to be further revealed. NSCLC cells (A549 and H1299) were treated with BBR. CCK8 assay, colony formation assay, flow cytometry, TUNEL staining and transwell assay were used to examine cell proliferation, apoptosis and invasion. The levels of spindle pole body component 25 (SPC25) and NDC80 kinetochore complex component (NUF2) were detected by qRT-PCR or western blot. The interaction between SPC25 and NUF2 was confirmed by Co-IP assay and FISH assay. Xenograft tumors were constructed to assess the anti-tumor role of BBR in vivo. BBR inhibited NSCLC cell growth, invasion and glycolysis. SPC25 was upregulated in NSCLC tissues, and BBR could reduce SPC25 expression in NSCLC cells. SPC25 knockdown repressed NSCLC cell growth, invasion and glycolysis, and its overexpression also reversed the anti-tumor effect of BBR. SPC25 could interact with NUF2, and NUF2 overexpression abolished the inhibitory effect of SPC25 knockdown or BBR on NSCLC cell behaviors. In animal experiments, BBR could suppress NSCLC tumor growth by inhibiting SPC25/NUF2 axis in vivo. BBR mainly played an anti-NSCLC role by targeting SPC25/NUF2 axis, which provided a new idea for NSCLC treatment.
Keywords: Berberine; NUF2; Non-small cell lung cancer; SPC25.
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Ethical approval: Our research was approved by the Ethics Committee of Third People’s Hospital of Zigong. Animal study was granted by the Animal Research Committee of Third People’s Hospital of Zigong. Consent to participate: Not applicable. Competing interests: The authors declare no competing interests.
References
-
- Baska A, Leis K, Galazka P (2021) Berberine in the treatment of diabetes mellitus: a review. Endocr Metab Immune Disord Drug Targets 21(8):1379–1386. https://doi.org/10.2174/1568026620666201022144405 - DOI - PubMed
-
- Chen M, Li S, Liang Y, Zhang Y, Luo D, Wang W (2021) Integrative multi-omics analysis of identified NUF2 as a candidate oncogene correlates with poor prognosis and immune infiltration in non-small cell lung cancer. Front Oncol 11:656509. https://doi.org/10.3389/fonc.2021.656509 - DOI - PubMed - PMC
-
- Chen Q, Hou Y, Li D, Ding Z, Xu X, Hao B et al (2022) Berberine induces non-small cell lung cancer apoptosis via the activation of the ROS/ASK1/JNK pathway. Ann Transl Med 10(8):485. https://doi.org/10.21037/atm-22-1298 - DOI - PubMed - PMC
-
- Chen QQ, Shi JM, Ding Z, Xia Q, Zheng TS, Ren YB et al (2019) Berberine induces apoptosis in non-small-cell lung cancer cells by upregulating miR-19a targeting tissue factor. Cancer Manag Res 11:9005–9015. https://doi.org/10.2147/CMAR.S207677 - DOI - PubMed - PMC
-
- Cui F, Xu Z, Lv Y, Hu J (2021) Role of spindle pole body component 25 in neurodegeneration. Ann Transl Med 9(18):1432. https://doi.org/10.21037/atm-21-4064 - DOI - PubMed - PMC
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical